CAS 151213-40-0

(4aS,7aS)-Octahydro-1H-pyrrolo[3,4-b]pyridine

Formula: C₇H₁₄N₂

InChI: InChI=1S/C7H14N2/c1-2-6-4-8-5-7(6)9-3-1/h6-9H,1-5H2/t6-,7+/m0/s1

InChI key: InChIKey=KSCPLKVBWDOSAI-NKWVEPMBSA-N

SMILES: [C@]12([C@@](CNC1)(NCCC2)[H])[H]

Synonyms:

• (1S,6S)-2,8-Diazabicyclo[4.3.0]nonane
• (1S,6S)-cis-2,8-Diazabicyclo[4.3.0]nonane
• (4AS,7aS)-Octahydro-1H-pyrrole[3,4-b]pyridine
• (4aS,7aS)-2,3,4,4a,5,6,7,7a-octahydro-1H-pyrrolo[3,4-b]pyridine dihydrochloride
• (4aS,7aS)-octahydro-1H-pyrrolo[3,4-b]pyridine
• (S,S)-2,8-Diazabicyclo[4,3,0]Nonane
• (S,S)-2,8-Diazabicyclo[4,3,0]Onoane
• (S,S)-2,8-Diazabicylco(4,3,0)Nonane
• 1H-Pyrrolo[3,4-b]pyridine, octahydro-, (4aS,7aS)-
• 1H-Pyrrolo[3,4-b]pyridine, octahydro-, (4aS-cis)-
• Cis-Octahydropyrrolo[3,4-B]Pyridine
• Moxifloxacin side chain

(1S,6S)-2,8-Diazabicyclo[4.3.0]nonane

CAS: 151213-40-0

Formula: C₇H₁₄N₂

Purity: >98.0%(GC)

Color and Shape: Colorless to Light orange to Yellow clear liquid

Molecular weight: 126.20

Ref: 3B-D4210

(1S,6S)-2,8-Diazabicyclo[4.3.0]Nonane

CAS: 151213-40-0

(1S,6S)-2,8-Diazabicyclo[4.3.0]Nonane

Formula: C₇H₁₄N₂

Purity: 98%

Molecular weight: 126.2

Ref: 54-OR1007933

1H-Pyrrolo[3,4-b]pyridine, octahydro-, (4aS,7aS)-

CAS: 151213-40-0

Formula: C₇H₁₄N₂

Purity: 97%

Color and Shape: Liquid

Molecular weight: 126.1995

Ref: IN-DA001N6U

(4aS,7aS)-Octahydro-1H-pyrrolo[3,4-b]pyridine

CAS: 151213-40-0

Color and Shape: Neat

Ref: 86-MM0885.15

(4S,7S)-Moxifloxacin Impurity 83

CAS: 151213-40-0

Formula: C₇H₁₄N₂

Molecular weight: 126.20

Ref: 4Z-M-27103

(S,S)-2,8-Diazabicyclo[4.3.0]nonane

Controlled Product

CAS: 151213-40-0

Applications Moxifloxacin intermediate

Formula: C₇H₁₄N₂

Color and Shape: Neat

Molecular weight: 126.2

Ref: TR-D416871

1H-Pyrrolo[3,4-b]pyridine, octahydro-, (4aS,7aS)-

CAS: 151213-40-0

Purity: 97%

Molecular weight: 126.2

Ref: 10-F861928

(1S,6S)-2,8-Diazabicyclo[4.3.0]nonane

CAS: 151213-40-0

(1S,6S)-2,8-Diazabicyclo[4.3.0]nonane is a chiral compound that can be made from the reaction of an organic acid with an amino alcohol. The enantiomers of this compound have shown to be effective against methicillin-resistant Staphylococcus aureus (MRSA) and Mycobacterium tuberculosis. The synthetic process for this compound was originally developed in the 1980s by researchers at the University of Illinois. They were able to show that it was possible to make a carbonyl reduction product using imidodicarbonic acid and an organic solvent. This led to the synthesis of moxifloxacin hydrochloride, which is used as a treatment for bacterial infections such as tuberculosis or pneumonia.

Formula: C₇H₁₄N₂

Purity: Min. 95%

Color and Shape: Colourless To Brown Liquid

Molecular weight: 126.2 g/mol

Ref: 3D-FD14784

(S,S)-2,8-Diazabicyclo[4.3.0]nonane

CAS: 151213-40-0

Formula: C₇H₁₄N₂

Molecular weight: 126.2

Ref: ST-EA-CP-M26100